Some time ago, Pfizer, the manufacturer of Lyrica had submitted what we call an sNDA (supplemental new drug application) to the FDA. This is what a manufacturer uses when they have a drug that has been approved for one use, and they are able to sell, but they want the FDA to add an approval to the drug's label.
However, in January 2010, Pfizer withdrew this sNDA from the FDA. This came along with cuts to a large number of research projects and drug approvals Pfizer was working on. Since the company that makes the drug is no longer actively seeking to get it approved for this new indication, it is very unlikely that we're going to see the FDA approve Lyrica for GAD in the near future.
While Pfizer always has the option of resubmitting this request, this cut came as a result of the buying up Wyeth, a drug company that got itself eviscerated in a protracted legal battle with the generic drug maker Teva. Pfizer apparently found itself spread too thing to pursue all these projects and goals.